
Quarterly report 2025-Q3
added 11-03-2025
IDEXX Laboratories Cash Flow 2011-2026 | IDXX
Annual Cash Flow IDEXX Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
929 M | 907 M | 543 M | 756 M | 648 M | 459 M | 400 M | 373 M | - | - | 236 M | 246 M | 222 M | 218 M |
Depreciation & Amortization |
130 M | 115 M | 112 M | 105 M | 96 M | 88 M | 83.2 M | 83.1 M | 78.2 M | 69 M | 58.9 M | 54.6 M | 52.4 M | 48.2 M |
Accounts Payables |
114 M | 111 M | 59.4 M | 64.4 M | 45.6 M | 72.2 M | 69.5 M | 67 M | 60.1 M | 52.6 M | 44.7 M | 29.9 M | 35.3 M | 36.6 M |
Accounts Receivables |
474 M | 457 M | 401 M | 368 M | 331 M | 269 M | 249 M | 235 M | 204 M | 188 M | 152 M | 158 M | 138 M | 141 M |
Total Inventories |
382 M | 380 M | 368 M | 269 M | 210 M | 195 M | 173 M | 164 M | 158 M | 189 M | 160 M | 133 M | 141 M | 133 M |
All numbers in USD currency
Quarterly Cash Flow IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 238 M | - | - | - | 199 M | - | - | - | 184 M | - | 370 M | - | 115 M | - | 546 M | - | 124 M | - | 429 M | 236 M | 27.9 M | - | 304 M | 171 M | 34.4 M | - | 264 M | 154 M | 34.9 M | - | 252 M | 141 M | 31.3 M | - | - | - | - | - | - | - | -14.6 M | - | - | 115 M | 33.5 M | - | 181 M | 102 M | 21.1 M | - | 153 M | 78.8 M | 15.2 M | - | 164 M | 88.3 M | 25.2 M |
Depreciation & Amortization |
- | - | 34.1 M | - | - | - | 29.9 M | - | - | - | 28.3 M | - | 83.2 M | - | 26.5 M | - | 76.9 M | - | 25.1 M | - | 71.4 M | 46.8 M | 23.2 M | - | 65.4 M | 43 M | 21.4 M | - | 62.6 M | 41.7 M | 20.8 M | - | 61.6 M | 40.9 M | 20.3 M | - | 58 M | 38.2 M | 18.5 M | - | 51.2 M | 32.9 M | 16.2 M | - | 43.6 M | 28.1 M | 13.4 M | - | 41.1 M | 27.4 M | 13.5 M | - | 38.5 M | 25.7 M | 12.7 M | - | 35.4 M | 23.3 M | 11.5 M |
Accounts Payables |
122 M | 117 M | 120 M | 114 M | 111 M | 117 M | 117 M | 111 M | 113 M | 108 M | 118 M | 110 M | 110 M | - | 121 M | 116 M | 86.7 M | 93 M | 87.2 M | 74.6 M | 74.6 M | 74.6 M | 74.6 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 69.5 M | 69.5 M | 69.5 M | 69.5 M | 67 M | 67 M | 67 M | 67 M | 60.1 M | 60.1 M | 60.1 M | 60.1 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M |
Accounts Receivables |
567 M | 561 M | 527 M | 474 M | 511 M | 534 M | 507 M | 457 M | 453 M | 462 M | 446 M | 401 M | 388 M | - | 402 M | 368 M | 377 M | 382 M | 382 M | 331 M | 331 M | 331 M | 331 M | 269 M | 269 M | 269 M | 269 M | 249 M | 249 M | 249 M | 249 M | 235 M | 235 M | 235 M | 235 M | 204 M | 204 M | 204 M | 204 M | 188 M | 188 M | 188 M | 188 M | 152 M | 152 M | 152 M | 152 M | 158 M | 158 M | 158 M | 158 M | 138 M | 138 M | 138 M | 138 M | 141 M | 141 M | 141 M | 141 M |
Total Inventories |
392 M | 393 M | 396 M | 382 M | 390 M | 380 M | 391 M | 380 M | 394 M | 395 M | 391 M | 368 M | 355 M | - | 302 M | 269 M | 258 M | 241 M | 226 M | 210 M | 210 M | 210 M | 210 M | 195 M | 195 M | 195 M | 195 M | 173 M | 173 M | 173 M | 173 M | 164 M | 164 M | 164 M | 164 M | 158 M | 158 M | 158 M | 158 M | 189 M | 189 M | 189 M | 189 M | 160 M | 160 M | 160 M | 160 M | 133 M | 133 M | 133 M | 133 M | 141 M | 141 M | 141 M | 141 M | 133 M | 133 M | 133 M | 133 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company IDEXX Laboratories, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
$ 19.02 | 0.21 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
$ 0.17 | -6.7 % | $ 4.99 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 20.15 | -2.3 % | $ 217 M | ||
|
Danaher Corporation
DHR
|
$ 228.92 | -0.76 % | $ 167 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
$ 66.37 | -1.03 % | $ 25.6 B | ||
|
BioNano Genomics
BNGO
|
$ 1.53 | 2.0 % | $ 1.94 M | ||
|
Castle Biosciences
CSTL
|
$ 38.9 | -1.04 % | $ 1.08 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
$ 11.38 | 6.36 % | $ 323 M | ||
|
IQVIA Holdings
IQV
|
$ 225.41 | -1.0 % | $ 40.9 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.56 | -0.33 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
$ 26.27 | -0.83 % | $ 794 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
$ 6.15 | -0.32 % | $ 557 M | ||
|
CareDx, Inc
CDNA
|
$ 18.84 | -1.21 % | $ 1.01 B | ||
|
NeoGenomics
NEO
|
$ 11.76 | -3.84 % | $ 1.49 B | ||
|
Celcuity
CELC
|
$ 99.74 | -0.18 % | $ 3.93 B | ||
|
National Research Corporation
NRC
|
$ 18.77 | 0.64 % | $ 461 M | ||
|
Anixa Biosciences
ANIX
|
$ 3.12 | - | $ 99.5 K | ||
|
Precipio
PRPO
|
$ 22.98 | -1.84 % | $ 29.8 M | ||
|
Personalis
PSNL
|
$ 7.96 | -0.13 % | $ 472 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
$ 102.14 | 1.53 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 4.53 | -4.83 % | $ 2.43 M | ||
|
Soleno Therapeutics
SLNO
|
$ 46.3 | 0.02 % | $ 1.86 B | ||
|
Illumina
ILMN
|
$ 131.16 | -1.2 % | $ 20.9 B | ||
|
Charles River Laboratories International
CRL
|
$ 199.48 | -1.24 % | $ 10.2 B | ||
|
Thermo Fisher Scientific
TMO
|
$ 579.45 | -0.69 % | $ 221 B | ||
|
Trinity Biotech plc
TRIB
|
$ 0.79 | -3.54 % | $ 61.9 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 173.53 | -1.12 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
$ 6.8 | 1.19 % | $ 882 M | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 250.88 | -0.87 % | $ 21 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 31.72 | -1.34 % | $ 1.9 B | ||
|
ICON Public Limited Company
ICLR
|
$ 182.22 | -0.43 % | $ 15 B | ||
|
Lantheus Holdings
LNTH
|
$ 66.55 | -0.91 % | $ 4.61 B |